Circulating miRNAs are associated with frailty and ST-elevation myocardial infarction pathways

Ramos, Juan Thomaz Gabriel de Souza; Pereira, Amanda Gomes; Ferrari, F.; Andrade, Meire Cristina Nogueira de; Melo, Caroline Souto de; Bôas, Paulo José Fortes Villas; Felix, Tainara F.; Carvalho, Marcelo; Dorna, Mariana de Souza; Azevedo, Paula Schmidt; Phillips, Bethan E.; Polegato, Bertha Furlan; Okoshi, Katashi; Bazan, Silméia Garcia Zanati; Paiva, Sérgio Alberto Rupp de; Zornoff, Leonardo Antônio Mamede; Reis, Patrícia P.; Minicucci, Marcos F.

doi:10.1016/j.archger.2022.104870

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings thus echo those from tissue-based miRNAs involved in frailty pathogenesis, supporting the clinical potentials of miRNAs as biomarkers. Another recent study disclosed that serum miR-103a-3p, miR-598-3p, and miR-130a-3p levels were differentially expressed between robust and frail individuals with myocardial infarction [ 43 ]. Others pinpointed serum miR-451a levels were increased significantly among frail older adults, serving as a potential frailty biomarker [ 44 ].…”

Section: Mirnas and Frail Kidney Phenotypementioning

confidence: 99%

Extracellular MicroRNAs as Potential Biomarkers for Frail Kidney Phenotype: Progresses and Precautions

2023

Aging dis

View full text Add to dashboard Cite

Frailty describes the cumulative subtle health deficits leading to an increased vulnerability to insults among older individuals or disease-laden ones. The prevalence of frailty increases substantially and relentlessly over declining renal function. Frailty in patients with chronic kidney disease (CKD) carries kidney-specific risk factors, clinical correlates and outcomes associations, hence alternatively termed frail kidney phenotype by researchers. Pathogenetically, miRNAs participate extensively in the development and aggravation of frailty, including the occurrence of frail kidney phenotype in CKD patients. These understandings spark profound interest in discovering biomarkers for identifying this detrimental phenotype, and extracellular miRNAs emerge as potentially useful ones. Pilot studies identify promising miRNA candidates for evaluating intermediates and surrogates of frail kidney phenotype, and more are underway. Several potential miRNA species in biologic fluids, such as circulating miR-29b and miR-223 (as inflammatory markers), exosomal miR-16-5p, miR-17/92 cluster members, and miR-106-5p (for uremic vasculopathy), serum exosomal miR-203a-3p (for uremic sarcopenia) have been examined and can be promising choices. Nonetheless, there remains research gap in affirming the direct connections between specific miRNAs and frail kidney phenotype. This stems partially from multiple limitations less well acknowledged before. From this perspective, we further outline the limitations and precautions prior to validating specific extracellular miRNA(s) for this purpose, from the definition of frailty definition, the functional and tissue specificity of miRNAs, the severity of CKD, and various technical considerations. It is expected that more affirmative studies can be produced for extending the utility of extracellular miRNAs in predicting frail kidney phenotype.

show abstract

Section: Mirnas and Frail Kidney Phenotypementioning

confidence: 99%

Extracellular MicroRNAs as Potential Biomarkers for Frail Kidney Phenotype: Progresses and Precautions

2023

Aging dis

View full text Add to dashboard Cite

show abstract

“…Over the past 15 years, a large number of experimental studies have contributed to clarifying the functions of several miRNAs involved in regulatory processes at the cardiac level [ 4 , 5 ]. Various studies have highlighted the pivotal role of certain miRNAs in hypertrophy, heart failure, and myocardial infarction, considering that they may be involved both in degenerative and reparative processes in cardiomyocytes [ 6 , 7 , 8 , 9 , 10 , 11 ]. Furthermore, given the intrinsic nature of the heart which is a muscle, several experimental studies focused on the involvement of the so-called myo-miRNAs as mediators and markers of cardiac damage [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Sessa

Salerno

Esposito

et al. 2023

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs), small noncoding RNAs, are post-transcriptional gene regulators that can promote the degradation or decay of coding mRNAs, regulating protein synthesis. Many experimental studies have contributed to clarifying the functions of several miRNAs involved in regulatory processes at the cardiac level, playing a pivotal role in cardiovascular disease (CVD). This review aims to provide an up-to-date overview, with a focus on the past 5 years, of experimental studies on human samples to present a clear background of the latest advances to summarize the current knowledge and future perspectives. SCOPUS and Web of Science were searched using the following keywords: (miRNA or microRNA) AND (cardiovascular diseases); AND (myocardial infarction); AND (heart damage); AND (heart failure), including studies published from 1 January 2018 to 31 December 2022. After an accurate evaluation, 59 articles were included in the present systematic review. While it is clear that miRNAs are powerful gene regulators, all the underlying mechanisms remain unclear. The need for up-to-date data always justifies the enormous amount of scientific work to increasingly highlight their pathways. Given the importance of CVDs, miRNAs could be important both as diagnostic and therapeutic (theranostic) tools. In this context, the discovery of “TheranoMIRNAs” could be decisive in the near future. The definition of well-setout studies is necessary to provide further evidence in this challenging field.

show abstract

Forensic significance of intracardiac expressions of Nrf2 in acute myocardial ischemia

Hiyamizu,

Ishida,

Yasuda

et al. 2024

Sci Rep

View full text Add to dashboard Cite

When exposed to oxidative and electrophilic stress, a protective antioxidant response is initiated by nuclear factor erythroid 2-related factor 2 (Nrf2). However, the extent of its importance in the forensic diagnosis of acute ischemic heart diseases (AIHD), such as myocardial infarction (MI), remains uncertain. On the other hand, immunohistochemical analyses of fibronectin (FN) and the terminal complement complex (C5b-9) prove valuable in identifying myocardial ischemia that precedes necrosis during the postmortem diagnosis of sudden cardiac death (SCD). In this study, we investigated the immunohistochemical levels of Nrf2, FN, and C5b-9 in human cardiac samples to explore their forensic relevance for the identification of acute cardiac ischemia. Heart samples were obtained from 25 AIHD cases and 39 non-AIHD cases as controls. Nrf2 was localized in the nuclei of cardiomyocytes, while FN and C5b-9 were detected in the myocardial cytoplasm. The number of intranuclear Nrf2 positive signals in cardiomyocytes increased in AIHD cases compared to control cases. Additionally, the grading of positive portions of cardiac FN and C5b-9 in the myocardium was also significantly enhanced in AIHD, compared to controls. Collectively, these results indicate that the immunohistochemical investigation of Nrf2 combined with FN, and/or C5b-9 holds the potential for identifying early-stage myocardial ischemic lesions in cases of SCD.

show abstract

Circulating miRNAs are associated with frailty and ST-elevation myocardial infarction pathways

Cited by 3 publications

References 32 publications

Extracellular MicroRNAs as Potential Biomarkers for Frail Kidney Phenotype: Progresses and Precautions

Extracellular MicroRNAs as Potential Biomarkers for Frail Kidney Phenotype: Progresses and Precautions

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Forensic significance of intracardiac expressions of Nrf2 in acute myocardial ischemia

Contact Info

Product

Resources

About